Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects scheduled to undergo elective bilateral lower (mandibular) third molar extraction under local anesthesia.~2. Subjects must be generally healthy, ambulatory, able to understand and willing to comply with study procedures, study restrictions, assessments, and requirements per the discretion of the investigator.~3. Subjects must voluntarily sign written informed consent prior to any study-specific procedures.~4. Subjects must have a body mass index (BMI) greater than or equal to 19.0 to less than or equal to 35.0~Exclusion Criteria:~1. History of migraine or frequent headaches, low back pain, or other acute or chronic pain conditions.~2. Acute illness or unresolved local infection prior to surgery that can interfere with the conduct of the study.~3. Positive results on urine drug screen or alcohol breath test indicative of illicit drug (Cocaine Metabolites, Marijuana (THC), MDMA (Ecstasy) and Phencyclidine) or alcohol abuse at screening and/or prior to extraction procedure.~4. Positive results for the following (prescription included): Amphetamines, Barbiturates, Benzodiazepines, Methadone, Methamphetamine, Opiates, Oxycodone, and Tricyclic Antidepressants.~5. Frequent use of nicotine-containing products.~6. Excessive intake of caffeine-containing foods or beverages within 48 hours prior to surgery.~7. Routinely uses pain medication.~8. Currently taking any corticosteroid chronically (except for an inhaled steroid for pulmonary disease, and local topical or ophthalmic steroid) or has taken systemic corticosteroids within 4 weeks of the proposed date of surgery.~9. Currently taking central nervous system active drugs such as hypnotics, sedatives, monoamine oxidase inhibitors, sympathomimetic amines, benzodiazepines, tricyclic antidepressants, or serotonin norepinephrine reuptake inhibitors, and anticonvulsants for pain.~10. Donated blood products or had blood loss greater than 500 mL 30 days prior to Screening or between Screening and surgery.~11. Member or relative of study staff or the Sponsor directly involved in the study.~12. Previous participation in this study.~13. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 30 days prior to the Screening visit.~14. Currently receiving or have received within 7 days prior to investigational product administration in the study, any drug (s) that is metabolized by hepatic microsomal enzyme CYP 2D6.~15. Clinically significant disease or disorder which may put the subject at risk, influence the results or the subject's ability to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- DFN-15 (Celecoxib Oral Solution) 62.5 mg (Type: EXPERIMENTAL): Single dose containing 62.5 mg of celecoxib in 10 ml solution
- DFN-15 (Celecoxib Oral Solution) 125 mg (Type: EXPERIMENTAL): Single dose containing 125 mg of celecoxib in 10 ml solution
- DFN-15 (Celecoxib Oral Solution) 250 mg (Type: EXPERIMENTAL): Single dose containing 250 mg of celecoxib in 10 ml solution
- Placebo (Type: PLACEBO_COMPARATOR): Single dose containing 0 mg of celecoxib in 10 ml solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete